Avidity Partners Management’s Structure Therapeutics GPCR Stock Holding History

Avidity Partners Management’s Portfolio GPCR Stock Details GPCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.26M	Buy	98,000 +68,000	+227%	+$3.01M	0.84%	19
2026 Q1	$1.45M	Buy	+30,000	New	+$2.05M	0.29%	31
2024 Q4	–	Sell	-430,900	Closed	-$18.9M	–	72
2024 Q3	$18.9M	Sell	430,900 -644,100	-60%	-$24.9M	0.96%	41
2024 Q2	$42.2M	Buy	1,075,000 +211,000	+24%	+$8.66M	1.79%	18
2024 Q1	$37M	Sell	864,000 -216,000	-20%	-$9.11M	1.19%	31
2023 Q4	$44M	Buy	1,080,000 +580,000	+116%	+$33.2M	1.6%	28
2023 Q3	$25.2M	Buy	500,000 +462,200	+1,223%	+$14.9M	1.02%	44
2023 Q2	$1.57M	Buy	+37,800	New	+$1.06M	0.05%	90

Other funds holding GPCR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Jupiter Topco New York $245B AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Avidity Partners Management's GPCR Position: Q2 2026 in Review

Avidity Partners Management increased its Structure Therapeutics (GPCR) stake by 227% in Q2 2026, buying an estimated $3.01M and bringing the position to 98,000 shares worth $5.26M. The position accounts for 0.84% of the portfolio, ranked #19.

Avidity Partners Management first reported a position in GPCR in Q2 2023 and has held it in 8 quarters since. The position peaked at $44M in Q4 2023. 192 funds tracked by Wall St. Rank hold GPCR as of Q2 2026.

Avidity Partners Management held 98,000 shares of Structure Therapeutics worth $5.26M as of Q2 2026.
Avidity Partners Management bought 68,000 Structure Therapeutics shares in Q2 2026, an estimated $3.01M.
Structure Therapeutics made up 0.84% of Avidity Partners Management's portfolio in Q2 2026, its #19 holding.
Avidity Partners Management first reported a position in Structure Therapeutics in Q2 2023 and has held it in 8 quarters since.
Avidity Partners Management's Structure Therapeutics position peaked at $44M in Q4 2023.
192 funds tracked by Wall St. Rank held Structure Therapeutics as of Q2 2026.

Based on Avidity Partners Management's 13F filing for Q2 2026, filed 14 Aug 2026.